ArticleAnnals of surgical oncology2013
Lumican and versican are associated with good outcome in stage II and III colon cancer.
Article in Annals of surgical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study.Research and practice in thrombosis and haemostasis · 2025Article
- Gene expression and immunohistochemistry analysis of ADAMTS-1 and its substrates in odontogenic keratocyst.Diagnostic pathology · 2025Article
- Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging.Acta neuropathologica communications · 2023Article
- Multi-omics analysis reveals the prognostic and tumor micro-environmental value of lumican in multiple cancer types.Frontiers in molecular biosciences · 2023Article
- KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer.BMC cancer · 2022Article
- Lumican in Carcinogenesis-Revisited.Biomolecules · 2021Review
- Extracellular Matrix Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2021Review
- Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma.BioMed research international · 2021Article
- Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.Clinical proteomics · 2020Article
- Knockdown of Lumican Inhibits Proliferation and Migration of Bladder Cancer.Translational oncology · 2019Article
- 5-Year Survival in Gastric Adenocarcinoma with Epithelial and Stromal Versican Expression.Iranian journal of pathology · 2019Article
- MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.Oncotarget · 2018Article
- Extracting Fitness Relationships and Oncogenic Patterns among Driver Genes in Cancer.Molecules (Basel, Switzerland) · 2017Article
- Lumican expression in gastric cancer and its association with biological behavior and prognosis.Oncology letters · 2017Article
- Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.PloS one · 2017Article
- Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.British journal of cancer · 2016Article
- Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Clinical & experimental metastasis · 2016Article
- Increased Sushi repeat-containing protein X-linked 2 is associated with progression of colorectal cancer.Medical oncology (Northwood, London, England) · 2015Article
- Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy.Molecular and cellular therapies · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor stroma plays an important role in the progression and metastasis of colon cancer. The glycoproteins versican and lumican are overexpressed in colon carcinomas and are associated with the formation of tumor stroma. The aim of the present study was to investigate the potential prognostic value of versican and lumican expression in the epithelial and stromal compartment of Union for International Cancer Control (UICC) stage II and III colon cancer.
methodsClinicopathological data and tissue samples were collected from stage II (n = 226) and stage III (n = 160) colon cancer patients. Tissue microarrays were constructed with cores taken from both the center and the periphery of the tumor. These were immunohistochemically stained for lumican and versican. Expression levels were scored on digitized slides. Statistical evaluation was performed.
resultsVersican expression by epithelial cells in the periphery of the tumor, i.e., near the invasive front, was correlated to a longer disease-free survival for the whole cohort (P = 0.01), stage III patients only (P = 0.01), stage III patients with microsatellite-instable tumors (P = 0.04), and stage III patients with microsatellite-stable tumors who did not receive adjuvant chemotherapy (P = 0.006). Lumican expression in epithelial cells overall in the tumor was correlated to a longer disease-specific survival in stage II patients (P = 0.05) and to a longer disease-free survival and disease-specific survival in microsatellite-stable stage II patients (P = 0.02 and P = 0.004).
conclusionsProtein expression of versican and lumican predicted good clinical outcome for stage III and II colon cancer patients, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.